Ondine Biomedical (LSE:OBI) FCF Margin % : -1,951.76% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ondine Biomedical's Free Cash Flow for the six months ended in Jun. 2023 was £-4.98 Mil. Ondine Biomedical's Revenue for the six months ended in Jun. 2023 was £0.26 Mil. Therefore, Ondine Biomedical's FCF Margin % for the quarter that ended in Jun. 2023 was -1,951.76%.

As of today, Ondine Biomedical's current FCF Yield % is -42.88%.

The historical rank and industry rank for Ondine Biomedical's FCF Margin % or its related term are showing as below:

LSE:OBI' s FCF Margin % Range Over the Past 10 Years
Min: -2743.38 Med: -888.7 Max: -189.13
Current: -2034.65

During the past 13 years, the highest FCF Margin % of Ondine Biomedical was -189.13%. The lowest was -2743.38%. And the median was -888.70%.

LSE:OBI's FCF Margin % is ranked worse than
82.49% of 1045 companies
in the Biotechnology industry
Industry Median: -139.31 vs LSE:OBI: -2034.65

Ondine Biomedical FCF Margin % Historical Data

The historical data trend for Ondine Biomedical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical FCF Margin % Chart

Ondine Biomedical Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-2,743.38

-1,633.46

-355.10

-491.19

-2,607.77

Ondine Biomedical Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial															-100.69	-1,789.40	-3,309.64	-2,127.75	-1,951.76

Competitive Comparison of Ondine Biomedical's FCF Margin %

For the Biotechnology subindustry, Ondine Biomedical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ondine Biomedical's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's FCF Margin % falls into.

Ondine Biomedical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ondine Biomedical's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-10.066	/	0.386
	=	-2,607.77 %

Ondine Biomedical's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-4.977	/	0.255
	=	-1,951.76 %

Ondine Biomedical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ondine Biomedical (LSE:OBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (LSE:OBI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

OBIMF:USA

Address

1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6

Website

https://www.ondinebio.com

Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical (LSE:OBI) Headlines

No Headlines